Coca-Cola has struggled to integrate its $5.6 billion purchase of BodyArmor with Powerade, which led to more “disruption in the short-term” than expected, according to CEO James Quincey.
Body Armor’s sales declined in the latest quarter.
The Atlanta-based Coca-Cola is optimistic that BodyArmor will eventually complement Powerade, its other big offering in the sports-drink category, as it aims to better compete against industry heavyweight, Pepsi-owned Gatorade.
BodyArmor’s purchase is the largest acquisition in Coca-Cola’s history.
In 2018, Coca-Cola first paid an undisclosed sum for a 15% share in BodyArmor, which had revenues of around $250 million.
That amount increased to more than $1 billion in 2021 when it acquired the remaining shares of brand to increase the variety of beverages it offers.
Through the use of coconut water, low sodium and high potassium levels, the lack of artificial colors, and the addition of sugar in place of high fructose corn syrup, the fast-growing, healthier sports drink gained popularity among consumers.
The purchase of BodyArmor by Coca-Cola led to a big bet that the beverage would play a key role in building out its liquid offerings and repositioning the business into a “total beverage company.”
Coca-Cola’s U.S. sports-drink market share had slipped in recent months. Still, the Coke chief remains optimistic this year will be a turning point for BodyArmor.


China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
US Reviewing Visa Denial for Venezuelan Little League Team Barred from World Series
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 



